Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Cancer Cell International
Published in: Cancer Cell International 1/2016

Open Access 01-12-2016 | Retraction Note

Retraction Note: Psoriasin (S100A7) is a novel biomarker for lung squamous cell carcinoma in humans

Authors: Guijuan Liu, Qiang Wu, Guilan Liu, Xueying Song, Jihong Zhang

Published in: Cancer Cell International | Issue 1/2016

Login to get access

Excerpt

The editors are retracting this article [1] as it has been previously published in the International Journal of Clinical and Experimental Pathology [2] and it is therefore a redundant publication. The authors could not be reached by the journal for comment on the retraction. …
Literature
1.
2.
Liu G, Wu Q, Liu G, Song X, Zhang J. Knockdown of S100A7 reduces lung squamous cell carcinoma cell growth in vitro and in vivo. Int J Clin Exp Pathol. 2014;7(11):8279–89.PubMedPubMedCentral
Metadata
Title
Retraction Note: Psoriasin (S100A7) is a novel biomarker for lung squamous cell carcinoma in humans
Authors
Guijuan Liu
Qiang Wu
Guilan Liu
Xueying Song
Jihong Zhang
Publication date
01-12-2016
Publisher
BioMed Central
Published in
Cancer Cell International / Issue 1/2016
Electronic ISSN: 1475-2867
DOI
https://doi.org/10.1186/s12935-016-0316-3

Other articles of this Issue 1/2016

Cancer Cell International 1/2016 Go to the issue

Primary research

Inhibition of integrin β3, a binding partner of kallistatin, leads to reduced viability, invasion and proliferation in NCI-H446 cells

Primary research

Stress-induced endocytosis and degradation of epidermal growth factor receptor are two independent processes

Primary research

Induction of G1-phase cell cycle arrest and apoptosis pathway in MDA-MB-231 human breast cancer cells by sulfated polysaccharide extracted from Laurencia papillosa

Primary research

Prognostic value of CD44 expression in patients with hepatocellular carcinoma: meta-analysis

Primary research

Quince peel polyphenolic extract blocks human colon adenocarcinoma LS174 cell growth and potentiates 5-fluorouracil efficacy

Primary research

Comprehensive characterization of the patient-derived xenograft and the paralleled primary hepatocellular carcinoma cell line
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits